(MGTA) – Press Releases
-
Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement
-
Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan
-
Magenta Therapeutics to Explore Strategic Alternatives
-
Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety
-
Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial
-
Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates
-
Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial
-
Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights
-
Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting
-
Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference
-
Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors
-
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
-
Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference
-
Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights
-
Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway
-
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights
-
Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference
-
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
-
Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform
-
Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022
-
Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference
-
Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting
-
Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights
-
Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting
-
Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer
-
Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference
-
Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial
-
Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights
-
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August
-
Sema4 Closes Transaction with CM Life Sciences, Debuts as Publicly Traded AI-driven Genomic & Clinical Data Platform Company
-
Magenta Therapeutics Announces Update on U.S. FDA Investigational New Drug Application for MGTA-117 in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome
-
Former Magenta Therapeutics and Foundation Medicine CFO Jason Ryan to Join Sema4 Board of Directors
-
Magenta Therapeutics Appoints Caren Deardorf as Chief Commercial Officer
-
Magenta Therapeutics Appoints Thomas Beetham as Chief Legal Officer
-
Magenta Therapeutics Announces Additional Preliminary Positive Results from Ongoing Phase 2 Clinical Trial of MGTA-145 and Plerixafor in Patients with Multiple Myeloma at the American Society of Clini
-
Magenta Therapeutics to Participate in Goldman Sachs 42nd Annual Global Healthcare Conference
-
Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in May
-
Magenta Therapeutics Announces Positive Preliminary Results from Phase 2 Clinical Trial of MGTA-145 in Multiple Myeloma and Provides an Update on its Anticipated Clinical Study with MGTA-117
-
Magenta Therapeutics Announces $86.4 Million Common Stock Investment from Multiple Investors
-
Magenta Therapeutics Reports First Quarter Financial Results and Recent Program Highlights
-
Magenta Therapeutics Appoints David Nichols as Chief Technical Officer
-
Magenta Therapeutics to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Conference
-
Magenta Therapeutics Presents Final Phase 1 Results of MGTA-145 Stem Cell Mobilization Clinical Trial and Preclinical Data from Targeted Conditioning Program at the European Society for Blood and Marr
-
Magenta Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
-
Magenta Therapeutics Reports Fourth Quarter and Full-Year 2020 Financial Results and Recent Program Highlights
-
Magenta Therapeutics to Present Additional Data from Phase 1 MGTA-145 Stem Cell Mobilization Program and Preclinical Updates on Targeting Conditioning Program at Transplantation and Cellular Therapy (
-
Anne McGeorge, Former Managing Partner of Grant Thornton LLP, Joins CitiusTech’s Board of Directors and Chair of the Audit Committee
-
Magenta Therapeutics Highlights Recent Progress and Expected Timing of 2021 Milestones, Including Four Ongoing and Planned Clinical Trials
-
Magenta Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference
-
Magenta Therapeutics Announces Commencement of First Phase 2 Clinical Trial of MGTA-145 for Stem Cell Mobilization, Oral Presentation of MGTA-145 Phase 1 Results and Update on Targeted ADC Conditionin
Back to MGTA Stock Lookup